SupplementsEvidence ReviewAug 2026

Liposomal Glutathione: Does the Delivery System Fix the Absorption Problem?

The pitch is elegant. Glutathione gets taken apart in your gut, so wrap it in a fat bubble and it arrives intact. The pitch is also mostly untested. Searching the published human literature, we found one randomised trial that put a liposomal product beside a plain one in the same people, and in that trial the liposome came second to a completely different delivery system. Here is exactly what has been measured, in how many people, and where the evidence stops.

646 vs 518

24 h exposure, liposomal 300 mg vs standard 500 mg

n = 14

People in that head-to-head crossover

Placebo arms in the 4 week liposomal trial

This page is educational and not medical advice. It reports what named human trials measured and what their authors concluded, including the amounts those trials used, because you cannot judge a bioavailability claim without knowing what was compared against what. It does not tell you to take glutathione, to stop taking it, or what amount to use. Anything about your own body belongs with a doctor or a pharmacist who can see your situation.

What Liposomal Means

A liposome is a tiny sphere built from the same kind of fatty molecules your own cell membranes are made of. Phospholipids naturally arrange themselves into a double layer with water on both sides, and that double layer can close into a bubble with a watery pocket inside. Put a water-soluble molecule in that pocket and it is no longer floating free in your stomach contents. It is shielded behind a membrane.

For glutathione the appeal is obvious. Glutathione is a tripeptide, three amino acids in a chain, and a gut is very good at taking peptides apart. Wrapping it should mean fewer of those molecules meet the enzymes that dismantle them. Cui and colleagues, reviewing liposomes for oral peptide and protein drugs generally, describe exactly this logic: the bilayer membrane provides protection for the drug inside the compartment, and the high biocompatibility makes it easier for the body to absorb.

And in the same review, the catch. Cui and colleagues continue that the phospholipids which form those membranes are themselves subjected to various digestive enzymes and to mucosal adhesion in the digestive tract, and disintegrate before absorption. That is the whole argument in two sentences. The bubble protects the cargo, and the gut attacks the bubble. Which of those two wins is an empirical question, and it is the question the rest of this page is about.

The Head-To-Head Crossover

Searching PubMed for randomised human comparisons of glutathione delivery formats turns up one trial that gave the same people a liposomal product and a plain one and measured both. If others exist, they did not surface in that search. Solnier and colleagues published it in Antioxidants in 2026, registered as NCT06345950, and it answers the question more directly than anything else we found.

The design was a randomised crossover in 14 healthy adults, aged 21 or over, mean age 37.2 years, with a one-week washout between treatments. The abstract calls it double-blind, and the methods section walks that back: because the formulations differed in capsule type, participant blinding could not be fully guaranteed, so what was concealed was the allocation, kept from the principal investigator and from the staff assessing outcomes and analysing the data until the analyses were finished. Each person received all three products on separate visits after a nine-hour fast, and whole blood was sampled 11 times over 24 hours. The three products were named specifically, which matters more than you would think:

Liposomal: a soft-gel capsule from BioAbsorb Nutraceuticals, Ontario, holding 300 mg of L-glutathione.
Standard: two hard-gel capsules from NOW Foods holding 250 mg each, so 500 mg in total, the highest dose of the three.
Micellar: a soft-gel capsule from Natural Factors, British Columbia, holding 300 mg, using a different carrier system called LipoMicel.

Here is what came back, as the paper reported it at the doses actually administered. All values are mean plus or minus standard error of the mean, n equals 14.

Measure	Liposomal 300 mg	Standard 500 mg	Micellar 300 mg
24 h exposure (iAUC, µg·mL·h)	645.5 ± 165.0	517.8 ± 180.0	1287.5 ± 179.0
Peak rise (ΔCmax, µg/mL)	45.5 ± 10.7	42.8 ± 11.5	103.9 ± 11.8
Time to peak (Tmax, h)	15.8 ± 2.4	9.9 ± 2.2	13.6 ± 2.8

Read the liposomal column against the standard column first, because that is the comparison you are actually shopping. The liposomal soft gel delivered more 24 hour exposure than the standard capsules while carrying 200 mg less glutathione. On the mean, the delivery system bought something.

Now read the error bars. The gap between those two means is about 128, and the standard errors around them are 165.0 and 180.0. A difference smaller than the uncertainty on either side of it is not a result you can lean on. The peak rise tells the same story even more plainly: 45.5 against 42.8, a difference of under 3 with errors above 10 on both. And the paper reports pairwise significance testing only for micellar against standard. It publishes no pairwise test of liposomal against standard, so the trial simply does not answer whether that particular gap is real. The three-way test across all treatments was significant, but that test was being driven by the third column.

The finding the marketing will not repeat. The liposome came second. The micellar formulation reached roughly double the liposomal exposure and about 2.5 times the standard arm, on a lower dose than standard. Only that second gap was tested. Micellar against standard came back at p equals 0.0064 for 24 hour exposure and p equals 0.0003 for peak rise, both significant. The paper publishes no pairwise test of micellar against liposomal for either measure, so the doubling is a gap between two means and not a tested result. The single place the paper does compare those two head to head, the ratio of reduced to oxidised glutathione, the difference was not significant at p equals 0.1478. Their own summary sentence is worth carrying whole: both the liposomal and the micellar formulations increased baseline-adjusted whole-blood glutathione relative to the standard preparation, with the micellar one producing significantly greater incremental exposure over 24 hours. The first half is the one a liposomal product page would quote. The second half is why the trial exists.

One more layer, because the paper presents two sets of numbers and they are not interchangeable. The table above uses the doses as given. The paper also publishes a dose-normalised set that rescales the 500 mg standard arm down to a 300 mg equivalent so all three sit at the same nominal dose. Under that rescaling the standard arm falls from 517.8 to 359.6 and its peak rise falls from 42.8 to 25.7, which widens every gap. Rescaling like that assumes exposure rises in a straight line with dose, and the authors flag the problem themselves: nonlinear dose to exposure relationships cannot be excluded for a substance the body regulates on its own. Both sets are in the paper. A product page quoting only the flattering one is choosing.

Who Ran That Trial

A trial that concludes one commercial formulation beats two others invites an obvious question, and the paper answers it in its own conflicts statement rather than making anyone dig.

Most of the authors are employees of ISURA, described in the paper as a not-for-profit independent organisation. One author is the owner of the Factors Group of Companies, and the winning micellar product is a Natural Factors soft gel. A patent pending on the LipoMicel matrix lists four of the authors as inventors. The paper states in the same breath that no inventor benefits from that patent and that ownership belongs to InovoBiologic. It also carries the standard line that the funder had no role in the design, the analysis, the interpretation or the decision to publish, which has nothing to attach to, because the funding statement says no external funding was provided for the study. The harder disclosure is in that same funding statement: the LipoMicel and enteric soft-gel samples were supplied by the Factors Group of Nutritional Companies, the company the paper names one of the authors as owning. The acknowledgements separately thank InovoBiologic for providing LipoMicel samples for testing.

What to do with that. Not dismiss it. Almost all supplement bioavailability research is funded by someone selling a formulation, and this paper disclosed more than most, used mass spectrometry rather than the cheaper thiol assay, and measured whole blood rather than plasma alone. What the disclosure does change is how you read the losing arm. The liposomal product was the comparator in somebody else's trial. Nobody in that study had an interest in showing the liposome at its best, and we found no published trial in which the liposome is the product under test against a plain capsule.

Liposomal Tested On Its Own

The study most often cited for liposomal glutathione is Sinha and colleagues at Penn State, published in the European Journal of Clinical Nutrition in 2018 and registered as NCT02278822. It is a real trial with real measurements and it is much smaller than its citation count suggests.

Twelve people enrolled, all of them healthy non-smokers aged 50 to 80 who had taken no antioxidant supplements for at least a month. That age range is an inclusion criterion, not an accident, and it is missing from every product page that cites this study. Those 12 were randomised across two dose groups, 500 mg and 1000 mg per day, which is roughly six people per dose. Supplementation ran for one month with blood taken at baseline and at 1, 2 and 4 weeks. Nobody withdrew.

What they found: glutathione was up after one week, with maximum increases of 40 percent in whole blood, 25 percent in red cells and 28 percent in plasma, all reached at two weeks. Plasma 8-isoprostane, an oxidative stress marker, fell 35 percent, and the ratio of oxidised to reduced glutathione fell 20 percent. On immune measures, natural killer cell cytotoxicity rose by up to 400 percent by two weeks and lymphocyte proliferation by up to 60 percent. The authors noted no differences between the two dose groups, while adding that statistical power was limited by the small sample.

Two sentences from the authors that change how those numbers read.

On design: the study did not use a placebo control. The authors say so directly and call for future placebo-controlled randomised trials to confirm the specificity of the effects. Every percentage above is a change measured against the same person at the start, with nothing to separate the capsule from time, season, diet or the ordinary drift of a blood measurement.
On comparison: they write that a direct comparison between forms of glutathione has not been made, that liposomal effects were often greater than previously observed for non-liposomal glutathione, and then that future side-by-side comparison studies will be required to establish the relative effectiveness of these forms. The middle clause is the one that gets quoted. The clause after it is the one that matters.

The paper also carries a funding disclosure: two authors received research funding from Researched Nutritionals, the company that supplies the liposomal glutathione product used, and the paper records that the company provided funding and product but did not take part in the design, the data analysis or the decision to publish. Same pattern as the crossover, opposite direction.

The Trials In People Already Ill

The longest and best-controlled work on oral liposomal glutathione was not done in healthy shoppers. It was done in two clinical populations chosen because they are known to run low on glutathione, and the results belong to those populations rather than to everybody.

People with HIV infection, 13 weeks

Ly and colleagues supplemented HIV-positive individuals with liposomal glutathione for 13 weeks and reported significant increases in the T-helper 1 cytokines interleukin-1 beta, interleukin-12, interferon gamma and tumour necrosis factor alpha, along with lower free radicals and lower immunosuppressive cytokines, relative to a placebo-controlled cohort. The tuberculosis part of that paper, the part the title leads with, was done in vitro: assays on blood cells collected from those participants after supplementation, not infections observed in the participants themselves.

People with type 2 diabetes, 3 months

To and colleagues gave oral liposomal glutathione or placebo to people with type 2 diabetes for three months. Note the verb in their conclusion: supplementation was able to maintain glutathione levels and prevent depletion in a population the authors describe as already glutathione deficient, and to reduce oxidative stress across blood components. Under that verb sits a split result. Reduced glutathione held steady in plasma and in white cells, with no significant change from before to after, and it rose significantly in red cells. The placebo group fell in all three. So the headline is maintenance, and inside it there was one real increase. The reduction in mycobacterial burden they also report came from granulomas generated in vitro from participants' blood cells, not from anything measured in a patient.

Both are legitimate studies with placebo comparison, which puts them ahead of the healthy-volunteer work on design. Neither tells a healthy 30 year old in Ho Chi Minh City what a capsule will do for them, because a deficient system and a replete one do not respond the same way, and neither trial compared the liposomal form against a plain one.

Apply the same funding question to these two that we applied to the crossover, because they do not pass it any more cleanly. Both came out of one laboratory, Vishwanath Venketaraman's group at Western University of Health Sciences, so they are not two independent lines of evidence. Both were funded in part by Your Energy Systems, the company that manufactures and holds the patent on the ReadiSorb liposomal glutathione they tested, and which also manufactured the empty-liposome placebo used in the diabetes trial. And both then declare no conflict: the HIV paper states that no competing financial interests exist, the diabetes paper states that the research was conducted in the absence of any commercial or financial relationships that could be construed as a conflict. Those declarations sit on the same pages as the funding lines.

Why The Gut Is Hard On A Liposome

It helps to understand why this is not a solved engineering problem, because the marketing presents the liposome as a finished technology rather than an active research area.

A liposome is made of fat, and your small intestine is purpose-built to dismantle fat. Bile salts emulsify it and lipase cleaves it. Cui and colleagues put it plainly in their review of oral peptide liposomes: the phospholipids that form the membrane are subjected to digestive enzymes and mucosal adhesion, and they disintegrate before absorption. Their review is about strategies to fix that, modifying the lipid composition or the particle surface to survive longer, which tells you the base case does not survive well. The authors of the crossover trial reached for the same mechanism to explain their result, suggesting that smaller, more fragile liposomes could disintegrate under digestive action and lose the carrier effect, while adding that further studies would be required to assess that directly and that they had not characterised the physical properties of the products they compared.

The animal work is a useful check on expectations. Byeon and colleagues in South Korea built proliposome formulations of glutathione, characterised them properly at 168 to 176 nanometres with encapsulation efficiency around 55 to 59 percent, and then tested them in rats. Their best formulation reached 1.11 fold the bioavailability of pure glutathione, and the paper reports that difference as statistically significant. It also reached 1.08 fold that of a commercial capsule, and there the paper says the values were slightly higher than the commercial product although there were no statistically significant differences. Their conclusion says the proliposomes enhanced the poor bioavailability of glutathione and prolonged its duration of action. So an 11 percent edge over raw glutathione in a rat is a measured difference the authors could stand behind, and it is nothing like the transformation a bottle implies. Against a product already on the shelf, they found no difference they could call real. These are rat figures. They do not convert to a human number, and this page will not pretend otherwise.

The pattern across all of it. Every well-characterised comparison that has actually been run, in rats or in humans, lands the liposome somewhere between a few percent and a modest multiple ahead of plain glutathione, never in a different league. The large numbers in this field come from uncontrolled before-and-after studies, and the modest numbers come from the controlled comparisons. That ordering is the tell.

What The Word On The Label Does Not Tell You

Here is the part that no amount of trial reading resolves. Even if liposomal delivery works, the word liposomal on a bottle is a claim about a manufacturing intention, not a specification anyone verified for that batch.

A liposome has measurable properties. Particle size, encapsulation efficiency, zeta potential, and whether the structure is still intact after weeks in storage. The Byeon paper reports every one of those for its formulations, which is what makes it a characterisation study, and it tracked size, dispersity and zeta potential across four weeks with no meaningful drift. Note the storage condition though: those samples sat at 4 degrees C, refrigerated. We found no published run of the same measurements on a product held for weeks at room temperature in a warm climate, which is how most of this region actually stores a supplement. A retail label reports none of it. Nothing on a normal supplement panel distinguishes a properly built and stability-tested liposome from glutathione powder stirred into lecithin.

We looked for published independent characterisation of commercially sold liposomal glutathione products, the kind of work that would tell you how many of them contain what the word implies, and did not find any. That is not evidence the products are misrepresented. It is an absence of evidence either way, and it means the question cannot currently be answered from the literature. Even the crossover trial that tested a specific retail liposomal soft gel stated that it did not directly characterise the physical properties of the formulations it compared.

Two separate questions, and only one of them has a tool. Does the bottle contain the amount of glutathione it claims, and does the delivery system do anything. The first is answerable: batch-level analysis from a laboratory that did not sell you the product, which our guide to reading a certificate of analysis covers. The second is not answerable from any document a seller can hand you, and it is the one the premium is charged for.

Three Routes, Three Questions

Glutathione is sold at three price points and they are three different questions with three different bodies of evidence. Results do not transfer between them, and a seller quoting a study from one route to sell you another is the most common error in this whole category.

Route	The question it answers	Where the evidence sits
Swallowed capsule	Does any of it survive the gut at all	Decades of human data, argued both ways, duration matters more than the milligram number
Liposomal capsule	Does a carrier change that answer	One head-to-head crossover, one uncontrolled 4 week trial, two trials in clinical populations
Intravenous drip	Is skipping digestion worth the cost and risk	A separate literature plus regulator cautions across this region

This page has only covered the middle row. The swallowed-capsule question, including what the long trials found and what the number on the front of the bottle does and does not mean, is a full page of its own. So is the drip, which carries a regulatory picture that capsules do not.

Does swallowing it work Glutathione IV in Vietnam

The Short Version

The one randomised crossover we could find that tested a liposomal product against a plain one in the same people used 14 healthy adults. The liposomal arm at 300 mg beat the standard arm at 500 mg on the mean 24 hour exposure, 645.5 against 517.8, but the standard errors were 165.0 and 180.0 and no pairwise test of that specific comparison was published.
In that same trial the liposome came second. A micellar formulation reached 1287.5, roughly double the liposomal arm on the mean, and about 2.5 times the standard arm. Only the micellar against standard comparison was tested, at p equals 0.0064. No pairwise test of micellar against liposomal was published for exposure or peak rise.
That trial was run by people with a disclosed commercial interest in the winning formulation, which the paper states openly. Its funding statement records no external funding and says the tested samples were supplied by the Factors Group of Nutritional Companies, the company one of the authors owns.
The most-cited liposomal-only trial enrolled 12 healthy people aged 50 to 80, split across two doses, with no placebo arm, and its own authors called for side-by-side comparisons to establish relative effectiveness.
The two placebo-controlled trials were run in people with HIV infection and in people with type 2 diabetes. The diabetes authors framed their result as maintaining glutathione and preventing depletion: reduced glutathione held steady in plasma and white cells and rose significantly in red cells, while the placebo group fell in all three. Both trials came from one laboratory and both were funded in part by the company that makes the product they tested.
In rats, a properly characterised proliposome reached 1.11 fold the bioavailability of pure glutathione, reported as significant. Against a commercial capsule it reached 1.08 fold, which the paper reports as not statistically significant. Rat figures do not convert to human ones.
Nothing on a retail label states particle size, encapsulation efficiency or shelf stability, and we found no published independent characterisation of commercial liposomal glutathione products.
None of the liposomal trials in these sources measured a skin outcome.

Frequently Asked Questions

Is liposomal glutathione better absorbed than regular glutathione?+

One randomised crossover in 14 healthy adults gave the same people a liposomal soft gel at 300 mg, a standard capsule at 500 mg and a micellar soft gel at 300 mg on separate occasions. Over 24 hours the liposomal arm produced a higher mean whole-blood glutathione exposure than the standard arm, 645.5 against 517.8, despite the lower dose. But the standard errors were 165.0 and 180.0, wide enough to swallow that gap, and the authors published a pairwise significance test only for micellar against standard. They did not publish one for liposomal against standard. So the trial shows liposomal ahead on the mean and does not establish that the difference is real.

Which form won that trial?+

Not the liposome. The micellar formulation reached 1287.5 in the same measure, roughly double the liposomal arm and about 2.5 times the standard arm at a lower dose than standard. Only the second of those two gaps was tested. The paper reports micellar against standard at p equals 0.0064 for 24 hour exposure, which is significant, and it publishes no pairwise test of micellar against liposomal for exposure or for peak rise, so that doubling sits on the means untested. The one place the paper does compare those two directly, the ratio of reduced to oxidised glutathione, the difference was not significant at p equals 0.1478. The authors wrote that both the liposomal and the micellar formulations increased whole-blood glutathione relative to the standard preparation, with the micellar one producing significantly greater exposure. Both halves of that sentence matter.

How many people have actually taken liposomal glutathione in a published trial?+

Very few, and that is the honest headline. The head-to-head crossover used 14 healthy adults for a single dose each. The four-week trial that tested liposomal glutathione on its own enrolled 12 people aged 50 to 80, split across two dose groups, which is about six people per dose, and it had no placebo arm at all. The larger and longer studies were run in people with HIV infection and in people with type 2 diabetes, not in healthy buyers.

Does liposomal glutathione lighten skin?+

None of the liposomal trials in our sources measured a skin outcome. They measured blood glutathione, oxidative stress markers and immune markers. The skin research on glutathione was run on swallowed capsules and on intravenous drips, and both of those have their own pages here. Anyone quoting a skin result at you for a liposomal product is borrowing it from a different route and a different study.

Is a liposomal capsule the same thing as a glutathione IV?+

No. A liposome is an attempt to survive the digestive tract. An intravenous drip skips the digestive tract entirely, which is a different question with different evidence and a different regulatory picture, including cautions from drug regulators in this region. That is covered separately on our glutathione IV page.

Can you tell from the label whether a product is really liposomal?+

Not reliably. The word liposomal on a supplement label is a description of an intended manufacturing method, not a verified specification, and nothing on a standard label states the particle size, the encapsulation efficiency or whether the liposomes survived to the shelf. The head-to-head crossover itself noted that the physical properties of the formulations it compared were not directly characterised in that study. A batch-level certificate of analysis tells you what is in the product, but it does not answer the delivery question either.

Research And Sources

Every figure on this page comes from one of the papers below, read as published abstracts and, where the detail was not in the abstract, as the full text. Study designs, populations, funding disclosures and author caveats are reported as the papers state them. Where a study hedged, the hedge is carried through.

A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical Trial · Solnier J, Du M, Zhang Y, Roh YS, Kuo YC, Ibi A, Wood S, Hardy M, Gahler RJ, Chang C · Antioxidants (Basel) (2026) PMID:41897500
Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function · Sinha R, Sinha I, Calcagnotto A, Trushin N, Haley JS, Schell TD, Richie JP Jr · European Journal of Clinical Nutrition (2018) PMID:28853742
Liposomal Glutathione Supplementation Restores TH1 Cytokine Response to Mycobacterium tuberculosis Infection in HIV-Infected Individuals · Ly J, Lagman M, Saing T, et al. · Journal of Interferon & Cytokine Research (2015) PMID:26133750
Effects of Oral Liposomal Glutathione in Altering the Immune Responses Against Mycobacterium tuberculosis and the Mycobacterium bovis BCG Strain in Individuals With Type 2 Diabetes · To K, Cao R, Yegiazaryan A, et al. · Frontiers in Cellular and Infection Microbiology (2021) PMID:34150674
Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability · Byeon JC, Lee SE, Kim TH, Ahn JB, Kim DH, Choi JS, Park JS · Drug Delivery (2019) PMID:30843439
Recent Advances in Oral Peptide or Protein-Based Drug Liposomes · Cui J, Wen Z, Zhang W, Wu W · Pharmaceuticals (Basel) (2022) PMID:36145293